# A Phase II Clinical Study of HRS-7058 in Combination With Antitumor Drugs in Patients With Advanced Malignant Tumour

Source: https://onco.cc/trials/nct06915142/  
OnCo record `nct06915142` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Adebrelimab, Cetuximab and SHR-A2102 in advanced solid tumours, run by Shandong Suncadia Medicine Co., Ltd., now recruiting.

## Summary

A Phase II Clinical Study of HRS-7058 in Combination With Antitumor Drugs in Patients With Advanced Malignant Tumour is a phase 2 interventional study registered as NCT06915142 by Shandong Suncadia Medicine Co., Ltd., with 300 participants planned, started 2025-04-28 and due to reach its primary completion in 2026-12. Interventions recorded: HRS-7058 + SHR-1316, HRS-7058 + SHR-1316 + Platinum-containing doublet chemotherapy, HRS-7058 + Cetuximab, HRS-7058 + SHR-1826, HRS-7058 + SHR-1826 + SHR-1316 and HRS-7058 + SHR-A1202.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06915142
- Phase: 2
- Setting: An Phase II Clinical Study on the Safety, Tolerability and Efficacy of HRS-7058 in Combination With Antitumor Drugs in Subjects With Solid Tumors
- Sponsor: Shandong Suncadia Medicine Co., Ltd.
- Enrolled: 300

## Sources

- ClinicalTrials.gov NCT06915142: https://clinicaltrials.gov/study/NCT06915142

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Adebrelimab](https://onco.cc/drugs/adebrelimab/), [Cetuximab](https://onco.cc/drugs/cetuximab/), [SHR-A2102](https://onco.cc/drugs/shr-a2102/)
- companies: [Jiangsu Hengrui Pharmaceuticals](https://onco.cc/companies/hengrui/)

---
JSON: https://onco.cc/api/v1/entities/nct06915142.json